| Last Trade: |
131.58 |
| Trade Time: |
May 18 4:00 PM Eastern Daylight Time |
| Change: |
0.00 (0.00 %) |
| Prev Close: |
131.58 |
| Open: |
0.00 |
| Bid: |
0.00 |
| Ask: |
0.00 |
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
|
Date |
Name |
Title |
Volume |
Trade Price |
Holding Change |
|
5/3/2012
|
Cox John
|
EVP Pharmaceutical Oper & Tech
|
-765
|
$134.26
|
-5.91%
|
|
5/3/2012
|
Pawlicki Raymond
|
SVP, Chief Information Officer
|
-765
|
$134.26
|
-8.06%
|
|
5/2/2012
|
SCHENK LYNN
|
Director
|
-8,480
|
$135.00
|
-54.43%
|
|
5/2/2012
|
SCHENK LYNN
|
Director
|
-5,975
|
$135.00
|
-67.32%
|
|
5/2/2012
|
ALEXANDER SUSAN H
|
EVP, General Counsel
|
20,000
|
$44.73
|
196.37%
|
Data provided by Insiderslab.com. To read detailed Insider Trading Research Report for (BIIB), click here.
-
Biotech ETFs are hitting all-time highs and XBI looks like the best of the group. Because the ETF is already up 25% in 2012 and trading at an all-time high, I'd wait for a normal pullback to buy into the weakness.
Read More »
-
PDL BioPharma Inc. (PDLI) posted first quarter earnings of 30 cents per share, above the year-ago figure of 25 cents and the Zacks Consensus Estimate of 26 cents. Lower diluted weighted average ...
Read More »
Free Reports
|
|
